Clinical Research Collaborations

Share & Bookmark, Press Enter to show all options, press Tab go to next option
Print

As part of the TRIO-US mission, offering cutting edge therapies to patients being served by the Network, developing collaborations on novel treatments is essential.  TRIO-US prides itself on utilizing and partnering to maximize currently approved therapies or those under review for approval for cancer treatment.  Part of novel treatments includes not only new drugs or therapies, but different and new applications of approved therapies.  TRIO-US has a long history of partnering on clinical trials with novel agents or new applications or combinations of therapies for patients with cancer.  These clinical research collaborations (CRCs) have been in a variety of different formats.  Most often, they are three-way projects with a UCLA clinical researcher, TRIO-US, and an industry partner.  Sometimes these CRCs include 2 industry partners interested in a combination therapy trial of their respective compounds. TRIO-US or the industry partner held the IND when one was required.  Generally, TRIO-US holds the IND as the sponsor and manages all the necessary reporting requirements to the FDA and participating sites. The CRCs have been focused primarily on breast, lung, colorectal, and pancreatic cancer. Currently, TRIO-US is sponsoring several CRCs.  We have a long list of publications and/or presentations from those CRCs we have completed (link coming soon).

Current Studies

TRIO-US is always looking for opportunities to provide new therapies to our community of investigators and patients.  Currently, TRIO-US has 2CRCs open to enrollment.  One study, TRIO-US L06 is for patients with extensive small cell lung cancer (SCLC).  This SCLC study is looking at the differences in survival with combination therapy.  The other trial, TRIO-US B12, is for patients with hormone receptor positive (+) breast cancer that has low HER2 expression.  This trial studies the effect of a HER2 blocking agent with or without an aromatase inhibitor when given before surgery. 

In addition, to these trials, TRIO-US is consistently working on collaboration opportunities that extend beyond UCLA and the TRIO-US network. We partner on several large registrational trial concepts with our industry partners. These efforts focus on trial design and operational requirements while the industry partner manages the study once developed and often this is with our global CRO partner TRIO.

For a full listing of all currently enrolling TRIO-US clinical trials, use our Clinical Trials Search Tool.  Please note that the tool is intended for use as a guide only.  We recommend contacting the TRIO-US Network Site closest to your home to confirm clinical trial availability and/or to get further information about specific trials.  

Completed Studies

TRIO-US has completed more than twenty-five (25) clinical research collaborations (CRCs) since it began.  These studies have been conducted in breast, gastric, esophageal, ovarian, lung, pancreatic, and other advanced cancers. 

Study details coming soon!